Aleth LifeSci Brief: 20-24 Jul 2026
Burnham abolishes UK science department
ALETH / LIFESCI-BRIEF / 2026-07-24 / BURNHAM ABOLISHES UK SCIENCE DEPARTMENTAleth applies source-based research to the week’s most important developments, tracing each story back to original disclosures and authoritative sources wherever possible.
The week in five lines
Burnham abolished the UK science department.
Biotech M&A hit a new record.
Trump threatened 200% tariffs on imported generics.
Tempus AI agreed to acquire Personalis for $1.5bn.
J&J gained FDA approval for its first robotic surgery system.
In this edition
Monday: Samsung buys PolyPeptide; GSK drops camlipixant; Kolon phase 3 fail; Tempus buys Personalis
Tuesday: UK abolishes DSIT; record biotech M&A; Novartis-Myricx ADC; Freenome SPAC
Friday: FDA backs BPC-157; J&J myeloma combo; GSK strategy update
Monday 20 July
Samsung Biologics agreed to buy Swiss CDMO PolyPeptide Group for $1.8bn.
Samsung is offering CHF 44.31 a share in cash, valuing PolyPeptide’s equity near CHF 1.46bn ($1.8bn), a 40% premium to the undisturbed price on 10 April. PolyPeptide’s board backs the offer and its largest holder, with 55.7% of the shares, has committed to tender. Peptide contract manufacturers have become a choke point in weight-loss drugs. Samsung, until now a monoclonal-antibody house, is buying its way into that. Completion is expected by the end of 2026.
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share - PolyPeptide Group / Samsung Biologics
GSK is stopping development of camlipixant, a chronic-cough drug it paid $2bn for.
In the phase 3 CALM programme, CALM-1 hit its primary endpoint, a significant cut in 24-hour cough frequency at week 12 on the 50mg twice-daily dose, but CALM-2 missed the same endpoint at week 24 and the lower 25mg dose failed in both trials. GSK judged the benefit “unlikely to transform patient care” and stopped development in refractory chronic cough. The asset, a P2X3 antagonist it acquired in its 2023 Bellus Health buyout, continues in a phase 2b trial in IBS.
Kolon’s cell-based gene therapy for knee osteoarthritis failed its first late-stage US trial.
TissueGene-C (TG-C) missed both co-primary endpoints, pain and function, at month 12 in the phase 3 ACTiVION-II study, which the company put down to an unusually strong placebo response. A second late-stage trial, ACTiVION-I, reports in October.
Kolon TissueGene reports topline ACTiVION-II phase 3 results for TissueGene-C (TG-C) - Kolon TissueGene
Tempus AI agreed to buy Personalis for $1.5bn, pulling cancer genomics into its AI-driven platform.
The all-stock deal values Personalis at $16.25 a share, an enterprise value near $1.5bn net of Tempus’s existing stake, with Tempus able to pay up to half in cash. It folds Personalis’s tumour-profiling and molecular residual disease (MRD) testing, including its NeXT Personal assay, into Tempus’s precision-oncology business. Tempus expects to close late in 2026 or early in 2027.
Tempus to acquire Personalis, integrating MRD - Tempus AI
Tuesday 21 July
Andy Burnham used his first days as Prime Minister to abolish the science department.
The Department for Science, Innovation and Technology (DSIT) is being folded into an enlarged Department for Business, Innovation, Science and Trade under Jonathan Reynolds. Patrick Vallance, the former government chief scientific adviser, resigned as science minister. Life sciences leaders welcomed Reynolds’s return but voiced concern at losing both a standalone science department and Vallance. A new Minister for AI, Kanishka Narayan, gets a cabinet seat, with AI strategy moving into the Cabinet Office.
Ministerial appointments: July 2026 - Prime Minister’s Office (GOV.UK)
Departure of Lord Vallance as science minister causes concern - The Times
Billion-dollar biotech takeovers in 2026 have already passed the whole of 2025.
The Financial Times counted 37 acquisitions of $1bn or more so far in 2026, topping last year’s full-year record of 35 with five months still to run. The engine is the patent cliff: big pharma is sitting on cash from today’s blockbusters and buying its next decade of revenue. The 2026 trend is broad, with every major and a widening group of mid-sized and specialist buyers in the market.
Fervour over top-selling drugs fuels record biotech dealmaking - Financial Times
Novartis provided further colour on its $1.5bn Myricx Bio acquisition.
Chief executive Vas Narasimhan defended the deal on this week’s Q2 call. Struck earlier in July, it brings Novartis Myricx’s N-myristoyltransferase inhibitor payload, a different way of killing tumour cells from the ADCs already crowding oncology. Narasimhan, who had sat out the ADC land grab, said he moved because the chemistry was novel: “we would certainly look to expand that NMTi payload across more delivery vehicles and more drug targets.”
“We’ve been looking for a novel approach”: Why Novartis CEO ended his ADC holdout for the $1.5B Myricx deal - Fierce Biotech
Freenome went public through a $310m SPAC.
The multi-cancer early detection (MCED) company completed its combination with Perceptive Capital Solutions Corp and began trading on Nasdaq as FRNM, raising $310m gross. The listing, agreed with the Perceptive Advisors vehicle in December, hands one of the larger private names in liquid-biopsy screening public-market capital to push its colorectal and multi-cancer tests toward commercialisation.
Freenome debuts as a publicly traded company focused on blood-based early cancer detection - Freenome
Wednesday 22 July
Trump set a countdown to a 200% tariff on imported generic drugs
Generics escape duty for two years, then face a 100% tariff from August 2028 and 200% a year after that, unless their makers build in the US. The president cast it as reshoring “with a penalty to those Companies that decide not to build.” The exposure is real: generics are about 90% of US scripts and most are imported, >50% from India alone. Sandoz, among the largest suppliers, said it shares the affordability goal and would keep talking to Washington but that it was “too early to assess” the impact.
Truth Social post on a 200% tariff on imported generic drugs - Donald J. Trump, Truth Social
Sandoz to engage with US policymakers after Trump’s tariff plan - The Wall Street Journal
Novo Nordisk took Eli Lilly to court over false advertising of weight-loss drugs.
In a complaint filed in New Jersey federal court, Novo alleges Lilly ran “false and materially misleading“ ads for Zepbound and Mounjaro, “intentionally selected outdated studies,” and set its top doses against lower doses of Wegovy and Ozempic while leaving out newer high-dose semaglutide data. It wants an injunction and corrective advertising. Lilly’s campaign leans on the SURMOUNT-5 head-to-head trial where tirzepatide beat semaglutide on weight loss: “the only head-to-head, randomized clinical trial“.
Novo Nordisk v. Eli Lilly, complaint, D.N.J. (3:26-cv-09027) - Novo Nordisk / STAT News
The FDA approved GSK’s lung-cancer drug Jideytro, a week after its $10.6bn buyout.
Jideytro (zidesamtinib), a brain-penetrant ROS1 inhibitor, cleared for ROS1-positive non-small cell lung cancer in patients already treated with a ROS1 drug, nearly two months ahead of its September action date. It is GSK’s first approved lung-cancer medicine, and it arrived through Nuvalent, whose ~$10.6bn takeover GSK completed on 15 July. Approval rested on the phase 1/2 ARROS-1 trial, in which 44% of patients responded.
Crystalys raised $130m to push its once-daily gout pill into phase 3.
The Series B, led by Frazier Life Sciences alongside existing backers Novo Holdings and SR One, funds registration trials for dotinurad, an oral URAT1 inhibitor that lowers uric acid and is already approved across much of Asia. It follows a $205m Series A only ten months earlier, in September 2025.
Crystalys Therapeutics announces $130 million Series B financing to advance global phase 3 development of dotinurad for gout - Crystalys Therapeutics
The NIH put its weight behind AI, launching a $1.2bn Bio Genesis Mission.
The programme is the health agency’s slice of a wider federal Genesis Mission, set up by a November 2025 executive order to point AI at scientific problems across government. NIH names six targets, from forecasting biological systems to speeding drug development, and its director, Jay Bhattacharya, set a goal of halving the time from discovery to patient over ten years.
Genesis Mission: harnessing AI to transform American science - The White House
Thursday 23 July
Repligen agreed to buy BioLife Solutions for about $1.5bn
BioLife makes the biopreservation media and freezing products that keep cell and gene therapies alive from manufacturing to patient, so the deal moves Repligen further into that supply chain rather than into a drug. Terms are $31.00 a share, split $11.25 in cash and 0.1442 of a Repligen share, a 24% premium to the 90-day average, with close expected in Q4.
Repligen to acquire BioLife Solutions, expanding its cell-therapy capabilities - Repligen / BioLife Solutions
AstraZeneca won EU approval for its oral breast-cancer pill Etcamah, while the US decision waits.
Etcamah (camizestrant), a next-generation oral selective estrogen receptor degrader (SERD), is cleared with a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer once a tumour picks up an ESR1 mutation during first-line treatment. In the phase 3 SERENA-6 trial the combination cut the risk of progression or death by 56% (hazard ratio 0.44), lifting median progression-free survival to 16.0 months from 9.2. The FDA has extended its review in the US approval process.
J&J was cleared by the FDA to enter the surgical robotics market.
The agency granted De Novo authorisation to J&J’s Ottava system, a soft-tissue surgical robot with its arms built into the operating table rather than mounted on carts, for a broad set of general-surgery procedures. It sets up a three-way US contest with Intuitive Surgical‘s da Vinci, which holds about 80% of the market, and Medtronic‘s Hugo. J&J will start with selected US hospitals while it seeks more indications.
Johnson & Johnson receives FDA market authorization in the US for its OTTAVA Robotic Surgical System - Johnson & Johnson
Lilly’s retatrutide posted the largest phase 3 weight loss yet reported for an obesity drug, but did not significantly reduce cardiac events.
In two phase 3 trials, the triple hormone agonist (”triple-G”) took up to 22.6% off patients’ weight at 80 weeks, ahead of the GLP-1 drugs already on sale. But in TRIUMPH-3, run in people with established cardiovascular disease, it did not significantly cut major cardiac events, the hazard ratio of 0.82 too wide to tell apart from chance. The peak figure also came in below the roughly 24% seen in phase 2. Lilly plans to file for approval in Q1 2027.
Friday 24 July
An FDA advisory panel voted to loosen the rules on a barely characterised peptide, over its own scientists’ objections.
By 8 votes to 6, with one abstention, the Pharmacy Compounding Advisory Committee recommended adding BPC-157, alongside a second peptide, KPV, to the substances pharmacies may compound. FDA staff had advised against, citing a lack of evidence that BPC-157 works and a warning of low confidence in what the substance even is. Most of the members who voted yes have ties to the peptide industry, on a panel remade under Health Secretary Robert F. Kennedy Jr. The recommendation is non-binding.
J&J reported that pairing two of its bispecific antibodies cut the risk of myeloma getting worse by 89%.
In the phase 3 MonumenTAL-6 trial, the combination of Tecvayli (teclistamab) and Talvey (talquetamab), which hit two different targets, BCMA and GPRC5D, reduced the risk of disease progression or death by 89% (hazard ratio 0.11) and the risk of death by 62% against standard care, in patients with relapsed or refractory disease. J&J said the hazard ratio was the lowest yet reported for a bispecific combination in a phase 3 myeloma trial. The result strengthens J&J’s already leading myeloma franchise.
GSK’s new CEO, Luke Miels, will set out his strategy next week, his first big pitch since taking the top job in January.
The company has scheduled its Q2 results and a “portfolio growth opportunities” update in London for 28 July, and insiders expect the depth of the R&D pipeline, and an emerging oncology portfolio, to be the centrepiece. Miels, previously chief commercial officer, has already spent to reshape that pipeline, through the acquisitions of RAPT and Nuvalent.
ALETH · OPEN ACCESS RESEARCH